Seeking Alpha

Corcept Therapeutics (CORT) ramps up another 15% today, rising for a second day following an...

Corcept Therapeutics (CORT) ramps up another 15% today, rising for a second day following an upgrade yesterday by Piper Jaffray and analysts at Janney Capital beginning coverage of the stock with a Buy rating and a $3 price target. CORT climbed just over 10% on Thursday to close at $1.63 a share, its best finish since early November.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)